Genzyme Myozyme revised PDUFA date
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme's Pompe disease treatment Myozyme (alglucosidase alfa) has a revised user fee date of April 28 following FDA's 90-day extension. The extension is to provide time to review additional agency-requested information, Genzyme says. The company submitted the BLA July 28 (1Pharmaceutical Approvals Monthly August 2005, In Brief); the enzyme replacement therapy is receiving a priority review...
You may also be interested in...
Genzyme Myozyme BLA
Genzyme expects a priority review for its Myozyme (alglucosidase alfa) BLA for treatment of Pompe disease. The company submitted the application July 28, setting a priority review action date at Jan. 28. Pompe disease, which the firm estimates affects fewer than 10,000 people worldwide, is part of the same family of lysosomal storage disorders as mucopolysaccharidosis, Fabry and Gaucher disease...
US High Court Punts On ‘Objective Falsity’ FCA Standard
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Warning Letter Close-Outs – February 2021
No device-related close-out letters were released by the US FDA last month.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: